These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38512627)

  • 41. Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014.
    Horvat N; Nikolovski I; Long N; Gerst S; Zheng J; Pak LM; Simpson A; Zheng J; Capanu M; Jarnagin WR; Mannelli L; Do RKG
    Abdom Radiol (NY); 2018 Jan; 43(1):169-178. PubMed ID: 28765978
    [TBL] [Abstract][Full Text] [Related]  

  • 42. LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium-enhanced magnetic resonance imaging.
    Jang HJ; Choi SH; Choi SJ; Choi WM; Byun JH; Won HJ; Shin YM
    Eur Radiol; 2023 Aug; 33(8):5792-5800. PubMed ID: 37017700
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.
    Chen J; Kuang S; Zhang Y; Tang W; Xie S; Zhang L; Rong D; He B; Deng Y; Xiao Y; Shi W; Fowler K; Wang J; Sirlin CB
    Abdom Radiol (NY); 2021 Apr; 46(4):1530-1542. PubMed ID: 33040166
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplant According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma.
    Bae JS; Lee DH; Lee SM; Suh KS; Lee KW; Yi NJ; Lee KB; Kim H; Han JK
    AJR Am J Roentgenol; 2022 Jul; 219(1):86-96. PubMed ID: 35138137
    [No Abstract]   [Full Text] [Related]  

  • 45. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
    Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
    Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
    [TBL] [Abstract][Full Text] [Related]  

  • 46. LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison With Current LI-RADS Criteria.
    Xian MF; Huang Y; Xie WX; Pan KM; Zeng D; Huang H; Li MD; Xie XY; Kuang M; Lu MD; Chen LD; Wang W
    AJR Am J Roentgenol; 2022 Jul; 219(1):76-85. PubMed ID: 34910538
    [No Abstract]   [Full Text] [Related]  

  • 47. Comparison of CT and gadoxetic acid-enhanced MRI with liver imaging reporting and data system to assess liver tumors before resection.
    Chen MF; Ho MC; Kao JH; Hwang RM; Deng SB; Yen KC; Liang PC; Wu CH
    J Formos Med Assoc; 2024 Mar; 123(3):318-324. PubMed ID: 38044205
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MRI proton density fat fraction for estimation of tumor grade in steatotic hepatocellular carcinoma.
    Kupczyk PA; Kurt D; Endler C; Luetkens JA; Kukuk GM; Fronhoffs F; Fischer HP; Attenberger UI; Pieper CC
    Eur Radiol; 2023 Dec; 33(12):8974-8985. PubMed ID: 37368108
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease is associated with heterogeneous pattern of fat infiltration in skeletal muscles.
    Nachit M; Dioguardi Burgio M; Abyzov A; Garteiser P; Paradis V; Vilgrain V; Leclercq I; Van Beers BE
    Eur Radiol; 2024 Mar; 34(3):1461-1470. PubMed ID: 37658893
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Should Threshold Growth Be Considered a Major Feature in the Diagnosis of Hepatocellular Carcinoma Using LI-RADS?
    Park JH; Chung YE; Seo N; Choi JY; Park MS; Kim MJ
    Korean J Radiol; 2021 Oct; 22(10):1628-1639. PubMed ID: 34269533
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
    Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
    Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection.
    Shao S; Liang Y; Kuang S; Chen J; Shan Q; Yang H; Zhang Y; Wang B; J Fowler K; Wang J; B Sirlin C
    Bosn J Basic Med Sci; 2020 Aug; 20(3):401-410. PubMed ID: 31999940
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progression Rates of LR-2 and LR-3 Observations on MRI to Higher LI-RADS Categories in Patients at High Risk of Hepatocellular Carcinoma: A Retrospective Study.
    Ranathunga D; Osman H; Islam N; McInnes MDF; Munir J; van der Pol CB; Elfaal M; Walsh C
    AJR Am J Roentgenol; 2022 Mar; 218(3):462-470. PubMed ID: 34643108
    [No Abstract]   [Full Text] [Related]  

  • 54. Contrast-Enhanced Imaging Features and Clinicopathological Investigation of Steatohepatitic Hepatocellular Carcinoma.
    Chen K; Xu Y; Dong Y; Han H; Mao F; Wang H; Song X; Luo R; Wang WP
    Diagnostics (Basel); 2023 Apr; 13(7):. PubMed ID: 37046555
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LI-RADS category 5 hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MRI for early recurrence risk stratification after curative resection.
    Wei H; Jiang H; Zheng T; Zhang Z; Yang C; Ye Z; Duan T; Song B
    Eur Radiol; 2021 Apr; 31(4):2289-2302. PubMed ID: 33001306
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
    Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).
    Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
    Cancer Imaging; 2018 Dec; 18(1):48. PubMed ID: 30526674
    [TBL] [Abstract][Full Text] [Related]  

  • 58. LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features.
    Alhasan A; Cerny M; Olivié D; Billiard JS; Bergeron C; Brown K; Bodson-Clermont P; Castel H; Turcotte S; Perreault P; Tang A
    Abdom Radiol (NY); 2019 Feb; 44(2):517-528. PubMed ID: 30167771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
    Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
    Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Magnetic Resonance Imaging With Extracellular Contrast Detects Hepatocellular Carcinoma With Greater Accuracy Than With Gadoxetic Acid or Computed Tomography.
    Min JH; Kim JM; Kim YK; Cha DI; Kang TW; Kim H; Choi GS; Choi SY; Ahn S
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2091-2100.e7. PubMed ID: 31843599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.